How much revenue does Anhui Anke Biotechnology (Group) make?

Anhui Anke Biotechnology (Group) reported 2.54 billion CNY in revenue for fiscal year 2024, down 11.5% from 2.87 billion CNY in fiscal year 2023. In Q2 2025 revenue was 663.43 million CNY.

What is Anhui Anke Biotechnology (Group)'s largest business segment?

Biological Products, with 1.98 billion CNY or 75% of segment revenue in fiscal year 2025. Next: Chinese Patent Medicine (11%) and Synthetic drugs (6%).

Where does Anhui Anke Biotechnology (Group) make most of its revenue?

East China: 37% of revenue by region in fiscal year 2025, followed by Central and Southwest China (25%).

What companies are similar to Anhui Anke Biotechnology (Group)?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include ApicHope Pharmaceutical Group Co., Ltd. (300723.SZ), Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ), Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS), Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS).

Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) Stock

About Anhui Anke Biotechnology (Group) Co., Ltd.

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name....

At a glance

Anhui Anke Biotechnology (Group) reported revenue of 2.54 billion CNY for fiscal year 2024, down 11.5% from fiscal year 2023, and net income of 706.95 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 663.43 million CNY, up 3.2% from a year before. Its largest business segment, Biological Products, brought in 75% of segment revenue in fiscal year 2025; East China was the largest region with 37%.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.